California-based research and development company. Alliance has several patents regarding 'microbubble' compositions such as Imagent® that are intended to enhance ultrasound imaging and Imagent GI as a gastrointestinal MRI contrast agent. Another product is Oxygent™, a synthetic 'blood substitute'.

MRI Contrast Agents:

• Imagent GI

[This entry is marked for removal.]

GE Medical Systems and Amersham announced in April 2004 the completion of a share exchange acquisition of Amersham Health by GE. The result of this acquisition is the new GE Healthcare, based in the UK, totally owned by General Electric (GE).

Amersham plc, was a producer of contrast imaging agents used to enhance image quality in X-ray, magnetic resonance imaging, and ultrasound procedures. It was also a leading producer of radiopharmaceuticals used in nuclear medicine imaging. Amersham Health was the firm's imaging, diagnostics, and therapeutics segment. Amersham plc was involved in biotechnology research through its Amersham Biosciences unit, which made scanners, sequencers, microarrays, industrial separations, and other research supplies.

The company is a member of the Bracco Group, a highly innovative healthcare group and world leader in global integrated solutions for the diagnostic medical imaging field. The Bracco Group is headquartered in Milan, Italy. Its North American operations consist of Bracco Diagnostics and Bracco Research USA, both located in Princeton, New Jersey. Bracco Diagnostics is one of the fastest growing developers and marketers of diagnostic pharmaceuticals in North America, with products for various imaging applications, including Isovue® (iopamidol - X-ray contrast agent), ProHance® (gadoteridol - MRI contrast agent), SonoVue® (ultrasound contrast agent) and nuclear medicine products.
Gadoteridol has been available in Europe and the USA for several years. Holder of the Marketing Authorization: Bracco International B.V. - Strawinskylaan 3051 - 1077 ZX Amsterdam The Netherlands. (Contact: Kirk Deeter, Phone: +NL-303-838-8708)

MRI Contrast Agents:

A large network of interconnecting blood vessels at the base of the brain that when visualized resembles a circle, the arteries effectively act as anastomoses for each other. This means that if any one of the communicating arteries becomes blocked, blood can flow from another part of the circle to ensure that blood flow is not compromised.
The circle of Willis is formed by both the internal carotid arteries, entering the brain from each side and the basilar artery, entering posteriorly. The connection of the vertebral arteries forms the basilar artery. The basilar artery divides into the right and left posterior cerebral arteries. The internal carotid arteries trifurcate into the anterior cerebral artery, middle cerebral artery, and posterior communicating artery. The two anterior cerebral arteries are joined together anteriorly by the anterior communicating artery. The posterior communicating arteries join the posterior cerebral arteries, completing the circle of Willis.
The time of flight angiography MRI technique allows imaging of the circle of Willis without the need of a contrast medium (best results with high field MRI). A cerebrovasular contrast enhanced magnetic resonance angiography (MRA) depicts the circle of Willis in addition to the vessels of the neck (carotid and vertebral arteries) with one bolus injection of a contrast agent.

For Ultrasound Imaging (USI) see Cerebrovascular Ultrasonography at Medical-Ultrasound-Imaging.com.

(MRI-CA) Coronary angiography with dobutamine stress tagging (MR images are taken after the heart has been stressed by using a medication called dobutamine). Investigational noninvasive imaging as a diagnostic tool for evaluating stenosis, anatomy and flow effects in coronary arteries with dobutamine stress.

For Ultrasound Imaging (USI) see Stress Echocardiogram at Medical-Ultrasound-Imaging.com.